戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                   There was no evidence of a pharmacokinetic interaction.
2 itaxel dose is reduced to compensate for the pharmacokinetic interaction.
3 st likely related to P450, contribute to the pharmacokinetic interaction.
4 ) or cobicistat (COBI) may be complicated by pharmacokinetic interactions.
5 ersal in cancer treatment and drug-flavonoid pharmacokinetic interactions.
6 ose of the combination regimen and to assess pharmacokinetic interactions.
7 rotein cholesterol-occurred independently of pharmacokinetic interactions.
8                                There were no pharmacokinetic interactions.
9                                           No pharmacokinetic interactions among the bnAbs and no loss
10                        There are no apparent pharmacokinetic interactions among the drugs.
11           Omadacycline has minimal drug-drug pharmacokinetic interactions and a favorable safety prof
12 ated treatment regimens designed to minimize pharmacokinetic interactions and to potentiate immunosup
13 iated with EI ASMs, as this may suggest that pharmacokinetic interactions are associated with lowerin
14              For antiepileptic drugs (AEDs), pharmacokinetic interactions are the most notable type,
15                    By far the most important pharmacokinetic interactions are those involving cytochr
16                   Preliminary data showed no pharmacokinetic interaction between A + T.
17                       There is a significant pharmacokinetic interaction between capecitabine and S-w
18 ultaneous dosing, there was no evidence of a pharmacokinetic interaction between CsA and RAD.
19                Given the significance of the pharmacokinetic interaction between herbs and drugs, we
20 conducted a phase I/IIa study to investigate pharmacokinetic interaction between IVC and gemcitabine.
21                                    Thus, the pharmacokinetic interaction between oral SRL and CsA con
22                                  There is no pharmacokinetic interaction between paclitaxel and carbo
23 ESLD) (substudy 1) and to assess the lack of pharmacokinetic interaction between RAL and the immunosu
24 ent dose, seems well tolerated, with minimal pharmacokinetic interaction between the two agents.
25               Recent reports indicate that a pharmacokinetic interaction between these two drugs may
26                      There is no evidence of pharmacokinetic interaction between vesnarinone and gemc
27  coinfection; however, little is known about pharmacokinetic interactions between boceprevir and anti
28 A randomized, open-label study to assess the pharmacokinetic interactions between boceprevir and rito
29                                              Pharmacokinetic interactions between chemotherapy and hi
30 nsplant recipients, the authors describe the pharmacokinetic interactions between cyclosporine and th
31                Lack of clinically meaningful pharmacokinetic interactions between dorzagliatin and si
32                                              Pharmacokinetic interactions between hypothermia and med
33                               No significant pharmacokinetic interactions between leflunomide and met
34                              We investigated pharmacokinetic interactions between PDE-Is (cilostazol
35                                There were no pharmacokinetic interactions between PF-04958242 and ket
36  of data from these trials is complicated by pharmacokinetic interactions between the target cytotoxi
37 tudy evaluated potential pharmacodynamic and pharmacokinetic interactions between/among Delta9-THC, c
38  suggested that pharmacological, rather than pharmacokinetic, interactions between the parent drugs w
39                                              Pharmacokinetic interactions can involve CYP 2D6, which
40   Detailed mechanistic interrogation of this pharmacokinetic interaction demonstrated that lenalidomi
41                                   Because of pharmacokinetic interactions, drug doses were decreased
42 rsers have in many instances been limited by pharmacokinetic interactions exacerbating the clinical t
43                                    An FA/RIF pharmacokinetic interaction has not previously been desc
44                    Detrimental bidirectional pharmacokinetic interactions have been observed when tel
45        Finally, a general review of possible pharmacokinetic interactions is included to assist the H
46  dose reductions were planned because of the pharmacokinetic interactions known to occur with PSC 833
47 mbination with cyclosporine (CsA) produces a pharmacokinetic interaction, namely increases in the who
48 n of renal dysfunction seemed to be due to a pharmacokinetic interaction of RAPA to greatly increase
49                                         This pharmacokinetic interaction offers a mechanism that may
50                          The effects of this pharmacokinetic interaction on the synergism between SRL
51 udy investigated the efficacy, toxicity, and pharmacokinetic interactions resulting from simultaneous
52                                This two-part pharmacokinetic interaction study evaluated boceprevir w
53             An open-label, randomized, 3-arm pharmacokinetic interaction study in adult volunteers wa
54 toxicity profile without clinically relevant pharmacokinetic interactions, support the performance of
55 nd-generation drugs are less likely to cause pharmacokinetic interactions than their older counterpar
56 red administration of RAD+Neoral avoided the pharmacokinetic interactions that caused the elevated dr
57                        Except in the case of pharmacokinetic interactions, these toxicities are not d
58                                           No pharmacokinetic interaction was found.
59                                           No pharmacokinetic interaction was observed between cyclosp
60                                           No pharmacokinetic interaction was observed.
61  3-week schedule were well tolerated, and no pharmacokinetic interaction was observed.
62                                              Pharmacokinetic interactions were not responsible for th
63                                           No pharmacokinetic interactions were observed.
64 nticipated toxicities or clinically relevant pharmacokinetic interactions were observed.
65 tes CsA-induced renal dysfunction owing to a pharmacokinetic interaction, whereas CsA produces a phar
66 l of these products participate in potential pharmacokinetic interactions with anticancer drugs.
67                                              Pharmacokinetic interactions with antiretroviral drugs d
68  efficacious modulator that apparently lacks pharmacokinetic interactions with coadministered antican
69 ostazol and sildenafil did not have negative pharmacokinetic interactions with rifampin.